Replies to post #517083 on Anavex Life Sciences Corp (AVXL)

[LakeshoreLeo1953]

I do find requesting to prove a negative is the favorite tactic of the faithful.
Whether that be Anavex or the Lottery, it is not a tool I use investing.

[Jonjones325]

Good post. Shows why having expertise is so important. Unfortunately it seems like we didn’t have that when we started the trials. Now that we have much more data and some real professionals on board, hopefully we can make some lemonade. Not sure why you exited since starting a proper US trial will surely give our SP a boost. Only way to go is up from here. 

[mrices]

Thanks for sharing your thoughts Doc. Sorry for suggesting you were short AVXL - my mistake.
I appreciate your concerns about limitations of post-hoc analysis and why another trial is critical before approving a drug that will be used by millions. AVXL has learned a lot from earlier study and OLE data and should have no problem designing a new P3 that addresses shortcomings of previous trial. Also clear that it might not be successful. But, based on what we've learned to date, I think/hope it will prove Blarcamesine meaningfully slows cognitive decline and significantly improve the lives of both patients and their caregivers. I have not seen any AD drug with results as promising as Blarcamesine, but I'm sure there are some in development, which is why AVXL needs a sense of urgency and BP partner to get this across the finish line.
I still come down on the side of maintaining my investment and hope we get back on track over the next few months.

[Kentucky123]

Thank you for your detailed reasoning. I wish I knew more about the science but I do recognize good management. Only a person blind as a bat would think we have decent management. I lightened up considerably at $8.62 only because I got stopped out.
I still own too much stock and my hope is for a change in management or preferably a partnership. The big tell is that no big biotech players own the stock. The group of doctors that bought $50,000,000 worth at a discount at $20 sold it two days later at $26. Cantor Fitzgerald bailed after the first flop and now only second rate analyst cover the company. Biogen was the only company that even sniffed at the company. It is a sad commentary on the medical profession allows such sophistry to permeate research. The Alzheimer's Association in the US has ignored Anavex and recognizes the ineptitude of the research. There were a lot of red flags.

[The Cooler Cooler]

Damn, even I can understand the (hypothetical) trial you've designed.

[gerry57]

I think you have a typo at the end of first paragraph. I think you meant to type now rather than not, concerning enrollment and finish. As always your insight is helpful to myself and many others here

[frrol]

It's amazing Missling is still there; he should be shown the door. Governance is too weak, and it is in these situations where this clearly shows to be an issue.